WHO ICTRP trial
A medical records based multicenter real-world study of neoadjuvant therapy for…
ChiCTR2100046929 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2100046929 |
|---|---|
| Public title | A medical records based multicenter real-world study of neoadjuvant therapy for early HER2-positive breast cancer in China (CSBrS-015) |
| Scientific title | Efficacy and safety of trastuzumab and patuzumab combined with neoadjuvant chemotherapy in the treatment of early HER2 positive breast cancer: a national multicenter real world study |
| Primary sponsor | Peking University First Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | Retrospective study |
| Countries | China |
| Conditions | breast cancer |
| Interventions | Trastuzumab + Pertuzumab dual target therapy group :Nil;Trastuzuma single target therapy group :Nil |
| Registration date | May 31, 2021 |
| Target size | Trastuzumab + Pertuzumab dual target therapy group :0;Trastuzuma single target… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: